0.6275

4.49% -0.0295

After Hours: .6275

Monopar Therapeutics Inc (MNPR)

Overview News Price History Discussions Forecast

Monopar Therapeutics Inc stock is currently priced at $0.6275, with a 24-hour trading volume of 58,239. It has seen a -4.49% decreased in the last 24 hours and a -11.62% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.6557 pivot point. If it approaches the $0.6057 support level, significant changes may occur.

Previous Close:

$0.657

Open:

$0.65

24h Volume:

58,239

Market Cap:

$10.95M

Revenue:

Net Income/Loss:

$-9.48M

P/E Ratio:

-0.8149

EPS:

-0.77

Net Cash Flow:

$-7.61M

1W Performance:

-7.45%

1M Performance:

-11.62%

6M Performance:

+33.51%

1Y Performance:

-43.47%

1D Range:

$0.62

$0.65

52W Range:

$0.2739

$1.75

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name

Monopar Therapeutics Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

847 388 0349

Address

1000 Skokie Boulevard, Suite 350, Wilmette

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

MNPR's Discussions on Twitter

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-21	Initiated	ROTH Capital	Buy

Monopar Therapeutics Inc Stock (MNPR) Latest News

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

GlobeNewswire Inc.

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

GlobeNewswire Inc.

Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research

All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy

Zacks Investment Research

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

GlobeNewswire Inc.

Monopar Therapeutics Inc Stock (MNPR) Financials Data

Monopar Therapeutics Inc (MNPR) Net Income 2024

MNPR net income (TTM) was -$9.48 million for the quarter ending September 30, 2023, a +7.92% increase year-over-year.

Monopar Therapeutics Inc (MNPR) Cash Flow 2024

MNPR recorded a free cash flow (TTM) of -$7.61 million for the quarter ending September 30, 2023, a +4.33% increase year-over-year.

Monopar Therapeutics Inc (MNPR) Earnings per Share 2024

MNPR earnings per share (TTM) was -$0.72 for the quarter ending September 30, 2023, a +11.11% growth year-over-year.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.